Result for
Tag: treatment
April 30, 2021
The Impact on Infectivity and Neutralization Efficiency of SARS-CoV-2 Lineage B.1.351 Pseudovirus
An in-vitro comparison of SARS-CoV-2 spike pseudoviruses carrying mutations characteristic of the B.1.351 lineage (N501Y, K417N, and E484K) and the original D614G lineage found that the viruses in the B.1.351 lineage demonstrated increased infectivity in cellular assays. Additionally, the monoclonal antibody imdevimab neutralized all three B.1.351 lineage viruses, while neutralization by the monoclonal antibody casirivimab…
Tocilizumab in Patients Admitted to Hospital with COVID-19 (RECOVERY): A Randomised, Controlled, Open-Label, Platform Trial
A randomized, controlled, open-label study of 4,116 adults hospitalized with severe COVID-19 found that administration of the anti-inflammatory medication tocilizumab reduced mortality, increased the chances of successful hospital discharge, and reduced the chances of requiring invasive mechanical ventilation. During a 28-day follow-up period, patients who received tocilizumab were significantly more likely to be discharged from…
April 28, 2021
A Randomised Clinical Trial of Azithromycin versus Standard Care in Ambulatory COVID-19 – the ATOMIC2 Trial
[Pre-print, not peer-reviewed] In a 1:1 randomized open-label trial among ambulatory patients with mild-moderate COVID-19 in the UK (n=292), those randomized to receive the antibiotic azithromycin had no significance difference in death or hospitalization within 28 days compared to patients receiving standard care (OR=0.91, 95% CI: 0.43-1.92). Rates of respiratory failure, progression to pneumonia, all-cause…
April 20, 2021
Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York
No difference in ventilator-free days through 28 days (p=0.86) was observed between patients randomized to receive convalescent plasma (CP) vs standard plasma in a 4:1 randomized doubled-blind placebo-controlled trial (n=74). CP increased antibody levels by 14%, whereas standard plasma led to a 7% decrease. All-cause mortality through 90 days was non-significantly lower in the CP…
April 19, 2021
Impact of Convalescent Plasma Therapy on SARS CoV-2 Antibody Profile in COVID-19 Patients
Convalescent plasma (CP) treatment did not predict survival in a longitudinal analysis of plasma samples from hospitalized patients with COVID-19 (n = 16) treated with either CP or standard of care. Among 8 patients who died, marked declines in neutralization titers were observed prior to death, which CP treatment did not reverse. Irrespective of CP…
Randomized Comparative Clinical Trial to Evaluate Efficacy and Safety of PNB001 in Moderate COVID-19 Patients
[Pre-print, not peer-reviewed] Patients with moderate COVID-19 (n=40) randomized to treatment with the novel anti-inflammatory medication PNB001 had lower clinical severity scores assessed by the 8-point WHO Ordinal Scale for COVID-19 at day 14 than patients who received standard of care alone (score 0.2 vs. 1.1, p<0.05). The multicenter randomized trial did not detect a…
April 15, 2021
Role of Interferon Therapy in Severe COVID-19: The COVIFERON Randomized Controlled Trial
The interferon therapy IFNβ1a was associated with a shorter time to clinical improvement (TTCI) compared to control (HR: 2.4, 95% CI 1.1-5.2) among people with severe COVID-19 in a 1:1:1 randomized, placebo-controlled, open-label trial (n=60), but patients treated with IFNβ1b did not have a statistically significant different TTCI (HR: 1.4, 95% CI 0.6-3.2). The median…
April 14, 2021
Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study
Adults with COVID-19 who were not hospitalized and received the monoclonal antibody therapy bamlanivimab (n = 218) had a 63% lower 30-day hospitalization rate than those who did not receive the treatment (n = 185) in a case-control study conducted between November 20, 2020 and January 19, 2021. Odds of hospitalization was 4.2 times higher…
April 13, 2021
Inhaled Budesonide for COVID-19 in People at Higher Risk of Adverse Outcomes in the Community Interim Analyses from the PRINCIPLE Trial
[Pre-print, not peer-reviewed] The inhaled corticosteroid budesonide reduced time to recovery among older ambulatory SARS-CoV-2-infected adults by 3 days, according to an interim analysis of a randomized, open-label trial (PRINCIPLE Trial). In participants either 65 years and older without co-morbidities or less than 50 years with co-morbidities given 14 days of 800 mcg of budesonide…
Inhaled Budesonide in the Treatment of Early COVID-19 (STOIC): A Phase 2, Open-Label, Randomised Controlled Trial
Treatment with the inhaled corticosteroid budesonide within 7 days of onset of mild COVID-19 symptoms was associated with a 91% reduction in risk of an urgent care visit, an emergency department consultation, or hospitalization. In the per-protocol analysis of the randomized, open-label phase 2 trial, one of these three outcomes occurred in 14% (10 of…
Previous page Next page